Bicara Therapeutics (BCAX) Total Current Liabilities (2023 - 2026)

Bicara Therapeutics has reported Total Current Liabilities for 4 years, with the latest figure at $39.3 million in Q1 2026.

• For the quarter ending Q1 2026, Total Current Liabilities rose 105.75% year-over-year to $39.3 million; the trailing twelve-month figure through Mar 2026 stood at $39.3 million (up 105.75% YoY), and the FY2025 full-year result was $28.9 million, up 60.92% from the prior year.
• Total Current Liabilities for Q1 2026 stood at $39.3 million, up from $28.9 million in the prior quarter.
• The five-year high for Total Current Liabilities was $39.3 million in Q1 2026, with the low at $14.5 million in Q3 2024.
• Historically, Total Current Liabilities has averaged $21.7 million across 4 years, with a median of $18.6 million in 2024.
• Annual changes were most pronounced in 2024 — Total Current Liabilities grew 19.26% — and 2026, when it surged 105.75%.
• Bicara Therapeutics' Total Current Liabilities stood at $15.1 million in 2023, then advanced by 19.26% to $18.0 million in 2024, then surged by 60.92% to $28.9 million in 2025, then jumped by 35.89% to $39.3 million in 2026.
• The last three Total Current Liabilities figures came in at $39.3 million (Q1 2026), $28.9 million (Q4 2025), and $21.0 million (Q3 2025), per Business Quant data.